| 0.93 -0.27 (-22.51%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.32 |
1-year : | 1.51 |
| Resists | First : | 1.13 |
Second : | 1.29 |
| Pivot price | 1.08  |
|||
| Supports | First : | 0.86 |
Second : | 0.71 |
| MAs | MA(5) : | 1.16 |
MA(20) : | 1.04 |
| MA(100) : | 1.37 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 57.6 |
D(3) : | 74.7 |
| RSI | RSI(14): 38.1 |
|||
| 52-week | High : | 6.17 | Low : | 0.86 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SCNI ] has closed above bottom band by 18.9%. Bollinger Bands are 4.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.18 - 1.19 | 1.19 - 1.19 |
| Low: | 0.91 - 0.91 | 0.91 - 0.92 |
| Close: | 0.92 - 0.93 | 0.93 - 0.94 |
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Mon, 15 Dec 2025
This Is Why Scinai Immunotherapeutics Ltd.'s (NASDAQ:SCNI) CEO Compensation Looks Appropriate - simplywall.st
Tue, 02 Dec 2025
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances - PR Newswire
Mon, 06 Oct 2025
Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities - PR Newswire
Tue, 02 Sep 2025
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - PR Newswire
Tue, 29 Jul 2025
Scinai Immunotherapeutics stock soars on promising skin disease drug data - Investing.com
Thu, 12 Jun 2025
Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025 - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 5.28e+009 (%) |
| Held by Institutions | 10.3 (%) |
| Shares Short | 54 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.75e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 448.3 % |
| Operating Margin | -486.9 % |
| Return on Assets (ttm) | -39.6 % |
| Return on Equity (ttm) | 1 % |
| Qtrly Rev. Growth | 1.15e+006 % |
| Gross Profit (p.s.) | 21.61 |
| Sales Per Share | 474.24 |
| EBITDA (p.s.) | -1.01198e+006 |
| Qtrly Earnings Growth | 4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 1.05 |
| Dividend | 0 |
| Forward Dividend | 29530 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|